Sulfur Hexafluoride Microbubbles Injection Suppliers & Bulk Manufacturers
Available Forms: injection
Available Strengths: 60.7mg
Reference Brands: SonoVue(EU)
Category:
Contrast Agent
Sulfur hexafluoride microbubbles are ultrasound contrast agents that enhance imaging by reflecting sound waves, increasing tissue and blood flow visibility. They support detailed cardiac and vascular assessments, improve diagnostic accuracy, and enable real-time visualization of organ structures. Benefits include high-resolution imaging, safety, rapid excretion, and enhanced clinical decision-making worldwide.
Sulfur Hexafluoride Microbubbles injection is available in injection
and strengths such as 60.7mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sulfur Hexafluoride Microbubbles injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sulfur Hexafluoride Microbubbles injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sulfur hexafluoride microbubbles, marketed as Optison in the US and SonoVue in the EU, are approved as ultrasound contrast agents for cardiac and vascular imaging. Regulatory approval requires dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with safety and manufacturing regulations. For dossier preparation, regulatory pathways, and market access guidance, visit PharmaTradz. Proper regional adherence supports swift approval, safe administration, and worldwide availability, improving diagnostic certainty in cardiovascular and organ imaging across healthcare regions globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing